Multiple endocrine neoplasia type 1 natural history, complications and prognosis: Difference between revisions
Line 13: | Line 13: | ||
==Complications== | ==Complications== | ||
* Complications that can develop as a result of MEN-1 are as follows.<ref name="pmid19904212">{{cite journal| author=Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T et al.| title=Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. | journal=Genet Med | year= 2009 | volume= 11 | issue= 12 | pages= 825-35 | pmid=19904212 | doi=10.1097/GIM.0b013e3181be5c97 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19904212 }} </ref> | * Complications that can develop as a result of MEN-1 are as follows.<ref name="pmid19904212">{{cite journal| author=Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T et al.| title=Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors. | journal=Genet Med | year= 2009 | volume= 11 | issue= 12 | pages= 825-35 | pmid=19904212 | doi=10.1097/GIM.0b013e3181be5c97 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19904212 }} </ref> <ref name="pmid27811505">{{cite journal| author=Nell S, Borel Rinkes IH, Verkooijen HM, Bonsing BA, van Eijck CH, van Goor H et al.| title=Early and Late Complications After Surgery For MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. | journal=Ann Surg | year= 2016 | volume= | issue= | pages= | pmid=27811505 | doi=10.1097/SLA.0000000000002050 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27811505 }} </ref> | ||
:* [[Necrolytic migratory erythema]] | :* [[Necrolytic migratory erythema]] | ||
:* [[Hypoglycemia]] | :* [[Hypoglycemia]] |
Revision as of 17:11, 6 October 2017
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 natural history, complications and prognosis |
FDA on Multiple endocrine neoplasia type 1 natural history, complications and prognosis |
CDC on Multiple endocrine neoplasia type 1 natural history, complications and prognosis |
Multiple endocrine neoplasia type 1 natural history, complications and prognosis in the news |
Blogs on Multiple endocrine neoplasia type 1 natural history, complications and prognosis |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
The natural history largely depends on the manifestation and virulence of the manifestations. The manifestations of multiple endocrine neoplasia type-1 (MEN-1) usually develop in the first, second, or third decade of life. If left untreated, manifestations of MEN-1 may gradually worsen, and patients may die of complications of the disease. Life-threatening complications of MEN-1 include gastrointestinal bleeding, convulsions, hypokalemia, hypoglycemia, and venous thrombosis. Although many tumors associated with MEN-1 are benign, approximately half of people with MEN-1 eventually develop a cancerous tumor. The prognosis of MEN-1 is generally good with treatment. Development of pancreatic cancer is associated with poor prognosis.
Natural History
- The natural history of MEN-1 is difficult to delineate given the rarity of the disease.
- The manifestations of MEN-1 usually develop in the first, second, or third decade of life.
- The age at which MEN-1 develops may vary significantly, even among members of the same family.
- If left untreated, manifestations of MEN-1 may gradually worsen, and patients may die of complications of the disease.
Complications
Prognosis
- The prognosis of MEN-1 is generally good with treatment.
- Early death can occur due to the effect of hormones produced by these tumors. [3]
- Although many tumors associated with MEN-1 are benign, approximately half of people with MEN-1 will eventually develop a cancerous tumor. [4]
- The presence of pancreatic tumors is associated with a particularly poor prognosis among patients with MEN-1.
References
- ↑ Falchetti A, Marini F, Luzi E, Giusti F, Cavalli L, Cavalli T; et al. (2009). "Multiple endocrine neoplasia type 1 (MEN1): not only inherited endocrine tumors". Genet Med. 11 (12): 825–35. doi:10.1097/GIM.0b013e3181be5c97. PMID 19904212.
- ↑ Nell S, Borel Rinkes IH, Verkooijen HM, Bonsing BA, van Eijck CH, van Goor H; et al. (2016). "Early and Late Complications After Surgery For MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors". Ann Surg. doi:10.1097/SLA.0000000000002050. PMID 27811505.
- ↑ Conemans EB, Brosens LAA, Raicu-Ionita GM, Pieterman CRC, de Herder WW, Dekkers OM; et al. (2017). "Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group". Pancreatology. 17 (5): 766–772. doi:10.1016/j.pan.2017.07.196. PMID 28811081.
- ↑ Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT (2013). "Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors". Medicine (Baltimore). 92 (3): 135–81. doi:10.1097/MD.0b013e3182954af1. PMC 3727638. PMID 23645327.